Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

ValiRx (VAL) Share Price

Price 0.55p on 30-05-2025 at 18:25:10
Change 0.00p 0%
Buy 0.60p
Sell 0.50p
Buy / Sell VAL Shares
Last Trade: Buy 17,144.00 at 0.56p
Day's Volume: 496,599
Last Close: 0.55p
Open: 0.55p
ISIN: GB00BLH13C52
Day's Range 0.55p - 0.55p
52wk Range: 0.39p - 3.30p
Market Capitalisation: £2m
VWAP: 0.506446p
Shares in Issue: 374m

ValiRx (VAL) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 17,144 0.56p Ordinary
16:07:20 - 30-May-25
Buy* 233 0.60p Ordinary
14:43:06 - 30-May-25
Buy* 6,427 0.56p Ordinary
10:14:28 - 30-May-25
Sell* 400,000 0.50p Ordinary
10:01:06 - 30-May-25
Buy* 4,564 0.57p Ordinary
09:55:40 - 30-May-25
Buy* 16,966 0.57p Ordinary
08:50:34 - 30-May-25
Sell* 51,265 0.505p Ordinary
08:14:49 - 30-May-25
Buy* 3,000 0.59p Ordinary
13:58:39 - 29-May-25
Buy* 42,000 0.585p Ordinary
13:27:09 - 29-May-25
Buy* 3,361 0.595p Ordinary
13:15:52 - 29-May-25
See more ValiRx trades

ValiRx (VAL) Share Price History

Time period:
to
Date Open High Low Close Volume
30th May 2025 (Fri) 0.55 0.55 0.55 0.55 496,599
29th May 2025 (Thu) 0.55 0.55 0.55 0.55 593,540
28th May 2025 (Wed) 0.55 0.55 0.55 0.55 285,407
27th May 2025 (Tue) 0.55 0.55 0.55 0.55 358,243
26th May 2025 (Mon) 0.5075 0.5075 0.5075 0.5075 0
23rd May 2025 (Fri) 0.55 0.55 0.55 0.55 4,025,787
22nd May 2025 (Thu) 0.55 0.55 0.55 0.55 80,564
21st May 2025 (Wed) 0.55 0.55 0.55 0.55 647,942
20th May 2025 (Tue) 0.525 0.55 0.525 0.55 2,469,066
19th May 2025 (Mon) 0.525 0.525 0.525 0.525 302,682
16th May 2025 (Fri) 0.525 0.525 0.525 0.525 611,194
15th May 2025 (Thu) 0.525 0.525 0.525 0.525 200,828
14th May 2025 (Wed) 0.525 0.525 0.525 0.525 166,362
13th May 2025 (Tue) 0.55 0.55 0.525 0.525 670,056
12th May 2025 (Mon) 0.55 0.55 0.55 0.55 1,560,150
9th May 2025 (Fri) 0.55 0.55 0.55 0.55 498,834
8th May 2025 (Thu) 0.55 0.55 0.55 0.55 583,065
7th May 2025 (Wed) 0.55 0.55 0.55 0.55 615,155
6th May 2025 (Tue) 0.50 0.55 0.50 0.55 2,169,856
5th May 2025 (Mon) 0.4675 0.4675 0.4675 0.4675 0
2nd May 2025 (Fri) 0.50 0.50 0.50 0.50 1,284,727
1st May 2025 (Thu) 0.50 0.50 0.50 0.50 754,129
See more ValiRx price history

ValiRx (VAL) Regulatory News

Date Source Headline
20th May 2025 1:25 pm RNS Holding(s) in Company
12th May 2025 7:00 am RNS Inaphaea Deal Extension With Dominion
30th Apr 2025 7:00 am RNS Commercial Update
3rd Apr 2025 7:00 am RNS Termination of Letter of Intent with TheoremRx
27th Mar 2025 7:00 am RNS Directorate Changes and new Advisory Board
21st Mar 2025 11:07 am RNS Director Disclosure Update
24th Feb 2025 7:00 am RNS Conclusion of Evaluation Project
3rd Feb 2025 7:00 am RNS Inaphaea Evaluation and Commercial Use Agreement
30th Jan 2025 7:00 am RNS Extension of Evaluation Agreement
29th Jan 2025 7:00 am RNS New Evaluation and Option Agreement
See more ValiRx regulatory news

ValiRx (VAL) Share News

IN BRIEF: ValiRx extends agreement with Dominion Biotech

12th May 2025 21:40

ValiRx PLC - Essex-based life sciences company focusing on early-stage cancer therapeutics and women's health - signs an extension to the evaluation and commercial use agreement with UK based Dominion Biotech Ltd announced on April 30. Under the extension, Inaphaea will share access to results from a proprietary screen of around 3000 Food & Drug Administration approved drugs generated in a panel of patient derived cells. The drugs are approved for non-cancer applications and Dominion will mine the data for potential cancer applications, carrying out routine analysis to validate the most promising candidates at its own expense; the parties will agree and share any additional in-depth studies if required. The results of the analysis will be jointly owned, and both parties will share equally all costs associated with filing, prosecution and maintenance of any arising patents for any repurposed drugs. The parties will work together to commercialise any new assets either to the owner of the original drug compounds or alternative companies interested in the repurposed assets. All revenue generated will be equally shared after costs. Read More

TRADING UPDATES: Strategic Minerals sales up; 4Global wins contract

4th Apr 2025 18:29

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

LONDON MARKET OPEN: Europe, Asia down as investors digest US tariffs

3rd Apr 2025 09:01

(Alliance News) - London stocks slumped alongside Asian and European peers at Thursday's market open, as US tariff announcements and the prospect of trade war throws the global market into turmoil. Read More

ValiRx shares fall as ends collaboration with Imperial College London

24th Feb 2025 16:20

(Alliance News) - ValiRx PLC on Monday said it has decided to return the Dual Kinase project to Imperial College London for further development, and will have no further financial commitment to the programme. Read More

AIM WINNERS & LOSERS: Strong 2024 for Quadrise and Rosebank

31st Dec 2024 10:58

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More

See more ValiRx news
FTSE 100 Latest
Value8,772.38
Change55.93

Login to your account

Forgot Password?

Not Registered